Kiniksa Pharmaceuticals International (KNSA) Total Current Liabilities (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Total Current Liabilities for 10 consecutive years, with $171.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 45.34% year-over-year to $171.2 million; the trailing twelve-month figure through Jun 2026 stood at $171.2 million (up 45.34% YoY), and the FY2025 full-year result was $139.2 million, up 38.33% from the prior year.
• Total Current Liabilities advanced to $171.2 million in Q2 2026 per KNSA's latest filing, from $156.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $171.2 million in Q2 2026 and bottomed at $36.6 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $86.1 million across 5 years, with a median of $74.3 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities slipped 27.34% in 2023, then soared 79.46% in 2024.
• Over 5 years, Total Current Liabilities stood at $47.1 million in 2022, then surged by 35.27% to $63.7 million in 2023, then jumped by 58.05% to $100.6 million in 2024, then jumped by 38.33% to $139.2 million in 2025, then grew by 23.04% to $171.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $171.2 million, $156.6 million, and $139.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.